Australia markets closed

Virbac SA (0NM7.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
351.00+2.25 (+0.65%)
At close: 07:40AM GMT
Full screen
Previous close348.75
Open352.00
BidN/A x N/A
AskN/A x N/A
Day's range351.00 - 352.00
52-week range215.50 - 352.00
Volume8
Avg. volume810
Market capN/A
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    VIRBAC: 2023 ANNUAL RESULTS

    Revenue up 4.9%, enabling market share gains despite difficulties in 20232023 operating profitability1 at an all-time high of 23.2% of revenue Up 0.4 points compared to 2022 Strong momentum expected in 2024 Expected revenue growth of 4% to 6% at constant exchange rates and scopeOperating profitability1 expected to rise by 0,5 point CONSOLIDATED FIGURES AS OF DECEMBER 31in millions of € 2023 2022restated6 2023/2022 change Revenue 1 246.9 1 216.2 +2.5% Change at constant exchange rates and scope2

  • GlobeNewswire

    Virbac : Declaration of the number of shares and voting rights 02/2024

    DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsFebruary, 29 20248 458 000Gross total of voting rights : 12 774 320Net total* of

  • GlobeNewswire

    Virbac to take a leading position in Japan through the acquisition of Sasaeah

    Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million. Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues of about €75 million, of which 50% from vaccines. With strong footholds in Japan, Sasaeah d